Is a complete LBRX research report available?

No complete published report is available for LB Pharmaceuticals Inc (LBRX) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

LB Pharmaceuticals Inc (LBRX)

NASDAQ: LBRX · USD

$40.9

+1.90 (+4.9%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first LBRX analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	1.2B
Net income (ttm)	-39M
EPS (ttm)	-$2.59
Shares out	28.7M
Volume	513,939
Price target	$45.9	+12.2%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -39M
EPS (ttm): -$2.59
Market cap: 1.2B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All LBRX indicators

Market & fundamental data

Available fields

171

Groups with data

Currency

USD

Showing 171 of 171 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001691082
Company name	LB Pharmaceuticals Inc
Country	United States
Country code	US
Cusip	50180M108
Employees	35
Enterprise value	$811M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2025-09-11
Isin	US50180M1080
Last refreshed	2026-07-31
Market cap	$1.2B
Market cap category	Small-Cap
Price	$40.9
Price currency	USD
Sector	Healthcare
Sector PE	45.21
Sector PE Fwd	23.64
Sic	2834
Symbol	LBRX
Website	https://lbpharma.us

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-3.32%
FCF yield	-4.3%
P/B ratio	3.1x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-39M
Net Income Growth Years	1%
Profit Per Employee	$-1.1M
ROCE	-12.04
ROE	-19.55
ROIC	-13.89

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS Growth Quarters	3
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$393.5M
Cash	$365.6M
Current Assets	$389.1M
Current Liabilities	$10.9M
Debt	$3.5M
Debt Equity	$0.01
Equity	$378.7M
Liabilities	$14.8M
Long Term Assets	$4.4M
Long Term Liabilities	$3.9M
Net Cash	$362.2M
Net Cash By Market Cap	$30.87
Net Cash Growth	1,390.64%
Net Debt Equity	$-0.96
Tangible Book Value	$378.7M
Tangible Book Value Per Share	$13.21

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	35.68
Net Working Capital	$13.3M
Quick ratio	33.53
Working Capital	$378.2M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-4,085.3%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
200-day SMA	24.67
50-day SMA	31.07
50-day SMA vs 200-day SMA	50over200
All Time High	41.33
All Time High Change	-1.04%
All Time High Date	2026-07-30
All Time Low	13.36
All Time Low Change	206.14%
All Time Low Date	2025-09-26
ATR	2.53
Beta1y	1.22
Ch YTD	83.74
High	41.33
High52	41.33
High52 Date	2026-07-30
High52ch	-1.04%
Low	36.72
Low52	13.36
Low52 Date	2025-09-26
Low52ch	206.14%
Ma50ch	31.66%
Premarket Change Percent	0.51
Premarket Price	$39.2
Premarket Volume	489
Price vs 200-day SMA	65.82%
RSI	76.17
RSI Monthly	0
RSI Weekly	78.06
Sharpe ratio	1.79x
Sortino ratio	3.19
Total Return	-4,085.3%
Tr YTD	83.74
Tr1m	25.31%
Tr1w	18.14%
Tr3m	33.7%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	8
Analyst Count Top	6
Analyst Price Target Top	$48.17
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.82
Operating Income	$-45.1M
Price target	$45.88
Price Target Change	$12.18
Price Target Change Top	$17.78

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	18,100,254%
Float Percent	63.12%
Shares Insiders	0.82%
Shares Institutions	70.22%
Shares Out	28,676,652
Shares Qo Q	11.16%
Shares Yo Y	4,085.3%
Short Float	23.54%
Short Ratio	11.99
Short Shares	14.86

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-56.6M
Adjusted OCF	-56,493,000
Average Volume	320,365.7x
Bv Per Share	13.21
CAPEX	$-63,000
Ch1m	25.31
Ch1w	18.14
Ch3m	33.7
Ch6m	93.2
Change	4.87%
Change From Open	4.15
Close	39
Days Gap	0.69
Depreciation Amortization	324,000
Dollar Volume	21,020,105.1
Earnings Date	2026-08-11
Earnings Time	bmo
EBIT	$-46.1M
EBITDA	$-46.1M
EPS	$-2.59
F Score	0
FCF	$-50.4M
FCF EV Yield	-6.22x
FCF Per Share	$-1.76
Financing CF	396,393,000
Fiscal Year End	December
Founded	2,015
Income Tax	$1,000
Investing CF	-44,899,000
Ipr	172.7
Iprfo	115.3
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-12
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-26
Ma150	27.13
Ma150ch	50.75%
Ma20	33.94
Ma20ch	20.52%
Net CF	301,124,000
Next Earnings Date	2026-08-10
Open	39.27
Optionable	No
Position In Range	90.67
Post Close	40.9
Postmarket Change Percent	0.02
Postmarket Price	$40.91
Ppne	3,632,000
Pre Close	39
Price Date	2026-07-30
Ptbv Ratio	3.1
Relative Volume	1.6x
Share Based Comp	6,123,000
Tr6m	93.2%
Us State	New York
Volume	513,939

LB Pharmaceuticals Inc (LBRX)

Coverage state: Market snapshot only — no published research

Generate the first LBRX analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · LBRX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All LBRX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on LBRX

Frequently asked questions